4 studies found for:    "B cell prolymphocytic leukemia"
Show Display Options
Rank Status Study
1 Terminated Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: alvespimycin hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
2 Recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
3 Recruiting Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Biological: ofatumumab;   Drug: dinaciclib;   Other: laboratory biomarker analysis;   Other: pharmacological study
4 Recruiting Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Condition: Leukemia
Intervention: Drug: Nelarabine

Indicates status has not been verified in more than two years